Roche’s Avastin Fails to Win NICE Ovarian Cancer Backing
This article is for subscribers only.
Dec. 18 (Bloomberg) -- Roche Holding anti-tumor drugAvastin fails to win backing of U.K. health-cost regulator astreatment for advanced ovarian cancer in a draft decisionreleased today.
* National Institute for Health and Clinical Excellence